Uveitis is an inflammation of the uvea, which comprises the iris, ciliary body and choroid. Uveitis can lead to ocular damage and complete visual loss. Noninfectious etiologies for uveitis are the most common in the U.S.1 The estimated incidence of uveitis ranges from 25–52 per 100,000 in adults and five per 100,000 in children. The…
Search results for: FLARE
Genes, Not Diet, Main Determinant of Urate Levels
NEW YORK (Reuters Health)—Heredity plays a substantially larger role than diet in determining serum urate levels, according to new findings in BMJ. Nearly 25% of the variation in serum urate is attributable to common genetic variants, while dietary pattern explained less than 1%, Dr. Tanya J. Major of the University of Otago in Dunedin, New…
Trial Data Reveals the Limitations of Steroids in Giant Cell Arteritis Therapy
AMSTERDAM—Just how seldom prednisone is successful at inducing remission in giant cell arteritis (GCA), despite such a long history of use for the disease, is one of the many lessons to emerge from the data in the GiACTA trial, said the principal investigator of the trial, which is the largest ever in GCA and is…
For Residents, Mystery Patients Often Require Rheumatologist Advice
As a first-year internal medicine resident, I find myself consulting rheumatologists for just about every mystery patient in our hospital. Like many residents, I was initially intimidated by the complexity of this elusive field. At first glance, diagnosis and management seem completely inaccessible to a first-year resident. But several rheumatology consults later, I can confidently…
The 2018 ACR/ARHP Annual Meeting Program Preview
Save the date for the 2018 ACR/ARHP Annual Meeting, Oct. 19–24 in Chicago. Connect with your colleagues for an unmatched educational experience featuring exceptional sessions by leading rheumatology experts. The ACR/ARHP Annual Meeting is your gateway to global rheumatology education. With more than 450 sessions—including The Great Debate—the meeting provides boundless opportunities for professional development,…
HCQ Debate: Should Dose Be No More Than 5 mg/kg in All SLE Patients?
Multiple studies show that hydroxychloroquine (HCQ) has many benefits in systemic lupus erythematosus (SLE), including cardiovascular benefits, such as reducing coronary artery and thrombosis risks. HCQ can prevent disease flares, including in renal and central nervous system lupus, and is the only drug shown to prolong survival in lupus. However, guidelines released in 2016 by…
Sessions to Check Out During the 2018 ACR/ARHP Annual Meeting
With more than 450 sessions, the 2018 ACR/ARHP Annual Meeting, is your gateway to global rheumatology education. Here is a preview of a few sessions attendees can look forward to…
Delayed Care: Research Paints Complex Picture of Treatment Delays
AMSTERDAM—A variety of factors lead to delays in patients seeking medical care for rheumatoid arthritis—from the nature of symptoms to coping tendencies—requiring more awareness from physicians when managing patients, researchers said at EULAR: the Annual European Congress of Rheumatology. Longer delays in treatment bring about more emotional distress to patients, missed chances to ease symptoms…
Promote Pregnancy Wellness: Data Can Help Guide Pregnancy Management in Lupus
AMSTERDAM—Clinicians who are counseling women with systemic lupus erythematosus (SLE) have the benefit of an array of new insights into factors linked with increased risk of pregnancy loss, how SLE therapies affect pregnancy and data on outcomes of children born to mothers with SLE, an expert said in a session at EULAR: the Annual European…
Phase 2 Trial Results Suggest Baricitinib Is Effective for SLE
A recent study found that baricitinib improved symptoms of arthritis and rash in patients with active SLE, while maintaining a safety profile consistent with previous findings…
- « Previous Page
- 1
- …
- 36
- 37
- 38
- 39
- 40
- …
- 65
- Next Page »